Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06210243Phase 1Terminated

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Role: collaborator

NCT03393936Phase 1Terminated

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

Role: lead

NCT03960060Phase 1Terminated

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

Role: lead

NCT04511871Phase 1Active Not Recruiting

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Role: lead

NCT05128786Phase 1Terminated

CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas

Role: lead

All 5 trials loaded